News for AstraZeneca Stock (AZN)

AstraZeneca posts mixed results from lung cancer trial

Proactive Investors • 12/19/22

AstraZeneca's Forxiga gets EU approval recommendation for symptomatic chronic heart failure

Market Watch • 12/19/22

AstraZeneca's Imfinzi plus Imjudo recommended for approval in the EU

Market Watch • 12/19/22

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low Metastatic Breast Cancer

Business Wire • 12/19/22

ENHERTU® Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer

Business Wire • 12/19/22

FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA

Zacks Investment Research • 12/16/22

AstraZeneca's new drug application for Lynparza given more time by US FDA

Proactive Investors • 12/15/22

4 Large Drug Stocks to Watch in a Booming Industry

Zacks Investment Research • 12/14/22

AstraZeneca attractive in near term but patent cliffs loom, says broker

Proactive Investors • 12/14/22

AstraZeneca Stock Hits New Relative Strength Highs, Reaches Buy Zone

Investors Business Daily • 12/13/22

AstraZeneca Awards $4M to Nonprofit Organizations to Advance Health Equity

Business Wire • 12/13/22

AstraZeneca a ‘buy' for project pipeline potential – broker

Proactive Investors • 12/09/22

Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials

Business Wire • 12/09/22

Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer

Business Wire • 12/08/22

ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03

Business Wire • 12/07/22

2 Stocks That Could Surprise Investors in 2023

The Motley Fool • 12/01/22

AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal

Zacks Investment Research • 11/30/22

AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022

Business Wire • 11/30/22

AstraZeneca sells Ohio manufacturing plant to National Resilience

Proactive Investors • 11/30/22

Resilience to Establish a Biomanufacturing Partnership with AstraZeneca and Purchase AstraZeneca's Manufacturing Site in West Chester, Ohio

Business Wire • 11/29/22

AstraZeneca adds focus on personalised cancer cell therapy with US$320mln acquisition

Proactive Investors • 11/29/22

AstraZeneca to Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy

Business Wire • 11/29/22

C4X Discovery signs exclusive global licence with AstraZeneca

Proactive Investors • 11/28/22

C4XD Agreement with AstraZeneca

Accesswire • 11/28/22

C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme

GlobeNewsWire • 11/28/22